Suppr超能文献

确定 CKD 患儿最佳胆钙化醇剂量方案:一项随机对照试验。

Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial.

机构信息

Department of Pediatric Nephrology, St John's Medical College Hospital, Bengaluru, Karnataka, India.

Pediatric Renal Service, Renal Unit, King Edward Memorial Hospital, Pune, Maharashtra, India.

出版信息

Nephrol Dial Transplant. 2022 Jan 25;37(2):326-334. doi: 10.1093/ndt/gfaa369.

Abstract

BACKGROUND

The optimal treatment regimen for correcting 25-hydroxyvitamin D (25OHD) deficiency in children with chronic kidney disease (CKD) is not known. We compared cholecalciferol dosing regimens for achieving and maintaining 25OHD concentrations ≥30 ng/mL in children with CKD stages 2-4.

METHODS

An open-label, multicentre randomized controlled trial randomized children with 25OHD concentrations <30 ng/mL in 1:1:1 to oral cholecalciferol 3000 IU daily, 25 000 IU weekly or 100 000 IU monthly for 3 months (maximum three intensive courses). In those with 25OHD ≥30 ng/mL, 1000 IU cholecalciferol daily (maintenance course) was given for up to 9 months. Primary outcome was achieving 25OHD ≥30 ng/mL at the end of intensive phase treatment.

RESULTS

Ninety children were randomized to daily (n = 30), weekly (n = 29) or monthly (n = 31) treatment groups. At the end of intensive phase, 70/90 (77.8%) achieved 25OHD ≥30 ng/mL; 25OHD concentrations were comparable between groups (median 44.3, 39.4 and 39.3 ng/mL for daily, weekly and monthly groups, respectively; P = 0.24) with no difference between groups for time to achieve 25OHD ≥30 ng/mL (P = 0.28). There was no change in calcium, phosphorus and parathyroid hormone, but fibroblast growth factor 23 (P = 0.002) and klotho (P = 0.001) concentrations significantly increased and were comparable in all treatment groups. Irrespective of dosing regimen, children with glomerular disease had 25OHD concentrations lower than non-glomerular disease (25.8 versus 41.8 ng/mL; P = 0.007). One child had a 25OHD concentration of 134 ng/mL, and 5.5% had hypercalcemia without symptoms of toxicity.

CONCLUSION

Intensive treatment with oral cholecalciferol as daily, weekly or monthly regimens achieved similar 25OHD concentrations between treatment groups, without toxicity. Children with glomerular disease required higher doses of cholecalciferol compared with those with non-glomerular disease.

摘要

背景

目前尚不清楚纠正慢性肾脏病(CKD)患儿 25-羟维生素 D(25OHD)缺乏的最佳治疗方案。我们比较了不同剂量的胆钙化醇治疗方案,以实现和维持 CKD 2-4 期患儿的 25OHD 浓度≥30ng/mL。

方法

这是一项开放标签、多中心随机对照试验,将 25OHD 浓度<30ng/mL 的患儿按 1:1:1 随机分为三组,分别接受口服胆钙化醇 3000IU/天、25000IU/周或 100000IU/月治疗 3 个月(最多 3 个强化疗程)。对于 25OHD≥30ng/mL 的患儿,给予胆钙化醇 1000IU/天(维持疗程),最多 9 个月。主要结局为强化治疗结束时达到 25OHD≥30ng/mL。

结果

90 例患儿被随机分为每日(n=30)、每周(n=29)或每月(n=31)治疗组。强化治疗结束时,70/90(77.8%)例患儿达到 25OHD≥30ng/mL;三组 25OHD 浓度无差异(中位数分别为 44.3、39.4 和 39.3ng/mL;P=0.24),达到 25OHD≥30ng/mL 的时间也无差异(P=0.28)。血钙、血磷和甲状旁腺激素无变化,但成纤维细胞生长因子 23(P=0.002)和 klotho(P=0.001)浓度显著升高,且在所有治疗组中无差异。无论剂量方案如何,肾小球疾病患儿的 25OHD 浓度均低于非肾小球疾病患儿(25.8 与 41.8ng/mL;P=0.007)。1 例患儿 25OHD 浓度为 134ng/mL,5.5%的患儿出现无症状性高钙血症,无毒性症状。

结论

口服胆钙化醇每日、每周或每月方案强化治疗可在治疗组之间获得相似的 25OHD 浓度,且无毒性。与非肾小球疾病患儿相比,肾小球疾病患儿需要更高剂量的胆钙化醇。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验